Nymox Pharmaceutical (NYMX)

P/S ratio as of November 2024 (TTM): N/A

According to Nymox Pharmaceutical's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -6.34. At the end of 2023 the company had a P/S ratio of N/A.

P/S ratio history for Nymox Pharmaceutical from 2001 to 2023

PS ratio at the end of each year

Year	P/S ratio	Change
2023	N/A
2022	N/A
2021	N/A	-100%
2020	> 1000	2710.88%
2019	> 1000	380.81%
2018	283	-64.64%
2017	801	77.82%
2016	451	782.64%
2015	51.1	949.65%
2014	4.86	-92.24%
2013	62.7	-16.41%
2012	75.0	-13.31%
2011	86.5	-73.88%
2010	331	-3.46%
2009	343	43.16%
2008	240	-38.61%
2007	390	78.39%
2006	219	66.27%
2005	132	-40.86%
2004	222	-45.92%
2003	411	85.29%
2002	222	-39.98%
2001	370

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Abbott Laboratories ABT	4.95	N/A	🇺🇸 USA
Pfizer PFE	2.60	N/A	🇺🇸 USA
Quest Diagnostics DGX	1.92	N/A	🇺🇸 USA
Eli Lilly LLY	17.4	N/A	🇺🇸 USA
Johnson & Johnson JNJ	4.25	N/A	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Nymox Pharmaceutical (NYMX)

P/S ratio as of November 2024 (TTM): N/A